157 related articles for article (PubMed ID: 37684327)
1. Neoadjuvant chemotherapy reduces the levels of HMGB1 and E-cadherin in patients with breast cancer.
Su Q; Wang X; Zhu R; Liu C; Sun S
Sci Rep; 2023 Sep; 13(1):14791. PubMed ID: 37684327
[TBL] [Abstract][Full Text] [Related]
2. Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy.
Stoetzer OJ; Fersching DM; Salat C; Steinkohl O; Gabka CJ; Hamann U; Braun M; Feller AM; Heinemann V; Siegele B; Nagel D; Holdenrieder S
Tumour Biol; 2013 Feb; 34(1):81-90. PubMed ID: 22983919
[TBL] [Abstract][Full Text] [Related]
3. Identification of tumor biomarkers for pathological complete response to neoadjuvant treatment in locally advanced breast cancer.
Gopinath P; Veluswami S; Gopisetty G; Sundersingh S; Rajaraman S; Thangarajan R
Breast Cancer Res Treat; 2022 Jul; 194(2):207-220. PubMed ID: 35597840
[TBL] [Abstract][Full Text] [Related]
4. Individualized model for predicting pathological complete response to neoadjuvant chemotherapy in patients with breast cancer: A multicenter study.
Qian B; Yang J; Zhou J; Hu L; Zhang S; Ren M; Qu X
Front Endocrinol (Lausanne); 2022; 13():955250. PubMed ID: 36060977
[TBL] [Abstract][Full Text] [Related]
5. Tumor infiltrating neutrophil might play a major role in predicting the clinical outcome of breast cancer patients treated with neoadjuvant chemotherapy.
Geng SK; Fu SM; Ma SH; Fu YP; Zhang HW
BMC Cancer; 2021 Jan; 21(1):68. PubMed ID: 33446143
[TBL] [Abstract][Full Text] [Related]
6. Serum Tumor Marker Levels might have Little Significance in Evaluating Neoadjuvant Treatment Response in Locally Advanced Breast Cancer.
Wang YJ; Huang XY; Mo M; Li JW; Jia XQ; Shao ZM; Shen ZZ; Wu J; Liu GY
Asian Pac J Cancer Prev; 2015; 16(11):4603-8. PubMed ID: 26107211
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant chemotherapy of breast cancer with pirarubicin versus epirubicin in combination with cyclophosphamide and docetaxel.
Gu X; Jia S; Wei W; Zhang WH
Tumour Biol; 2015 Jul; 36(7):5529-35. PubMed ID: 25682286
[TBL] [Abstract][Full Text] [Related]
8. Potential value of tumor stiffness and sE-cadherin in predicting the response to neoadjuvant therapy in HER2-positive breast cancers.
Zhou W; Wu M; Lin H; Chen W; Lu G; Yang F; Chen Y; Chen G
Future Oncol; 2022 Aug; 18(25):2817-2825. PubMed ID: 35730465
[TBL] [Abstract][Full Text] [Related]
9. Circulating microRNA-451 as a predictor of resistance to neoadjuvant chemotherapy in breast cancer.
Gu X; Xue JQ; Han SJ; Qian SY; Zhang WH
Cancer Biomark; 2016; 16(3):395-403. PubMed ID: 27062696
[TBL] [Abstract][Full Text] [Related]
10. Identifying Circulating Tumor DNA Mutations Associated with Neoadjuvant Chemotherapy Efficacy in Local Advanced Breast Cancer.
Wei B; Shan Y; Du Z; Yin C; Zhang Q; Lin H; Zhang G; Song D; Zuo H
Appl Biochem Biotechnol; 2022 Sep; 194(9):3961-3973. PubMed ID: 35579744
[TBL] [Abstract][Full Text] [Related]
11. Combination of tumor markers predicts progression and pathological response in patients with locally advanced gastric cancer after neoadjuvant chemotherapy treatment.
Liu Z; Wang Y; Shan F; Ying X; Zhang Y; Li S; Jia Y; Miao R; Xue K; Li Z; Li Z; Ji J
BMC Gastroenterol; 2021 Jul; 21(1):283. PubMed ID: 34246249
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of HMGB1 in early breast cancer patients under neoadjuvant chemotherapy.
Exner R; Sachet M; Arnold T; Zinn-Zinnenburg M; Michlmayr A; Dubsky P; Bartsch R; Steger G; Gnant M; Bergmann M; Bachleitner-Hofmann T; Oehler R
Cancer Med; 2016 Sep; 5(9):2350-8. PubMed ID: 27457217
[TBL] [Abstract][Full Text] [Related]
13. Molecular types and neoadjuvant chemotherapy in patients with breast cancer- while molecular shifting is more common in luminal a tumors, the pathologic complete response is most frequently observed in her-2 like tumors.
Salim DK; Mutlu H; Eryilmaz MK; Musri FY; Tural D; Gunduz S; Coskun HS
Asian Pac J Cancer Prev; 2014; 15(21):9379-83. PubMed ID: 25422228
[TBL] [Abstract][Full Text] [Related]
14. TOPK: A new predictor of the therapeutic response to neoadjuvant chemotherapy and prognosis in triple-negative breast cancer.
Wang K; Chai J; Xu J; Wei J; Li P; Liu Y; Ma J; Xu T; Zhao D; Yu K; Fan L; Yan Q; Guo S; Li M; Wang Z
Pathol Res Pract; 2021 Oct; 226():153603. PubMed ID: 34500374
[TBL] [Abstract][Full Text] [Related]
15. DNA methylation changes in response to neoadjuvant chemotherapy are associated with breast cancer survival.
Pedersen CA; Cao MD; Fleischer T; Rye MB; Knappskog S; Eikesdal HP; Lønning PE; Tost J; Kristensen VN; Tessem MB; Giskeødegård GF; Bathen TF
Breast Cancer Res; 2022 Jun; 24(1):43. PubMed ID: 35751095
[TBL] [Abstract][Full Text] [Related]
16. Mammographic density as an image-based biomarker of therapy response in neoadjuvant-treated breast cancer patients.
Skarping I; Förnvik D; Heide-Jørgensen U; Sartor H; Hall P; Zackrisson S; Borgquist S
Cancer Causes Control; 2021 Mar; 32(3):251-260. PubMed ID: 33377172
[TBL] [Abstract][Full Text] [Related]
17. Assessment of therapeutic response of locally advanced breast cancer (LABC) patients undergoing neoadjuvant chemotherapy (NACT) monitored using sequential magnetic resonance spectroscopic imaging (MRSI).
Danishad KK; Sharma U; Sah RG; Seenu V; Parshad R; Jagannathan NR
NMR Biomed; 2010 Apr; 23(3):233-41. PubMed ID: 20175134
[TBL] [Abstract][Full Text] [Related]
18. Changes of serum miR34a expression during neoadjuvant chemotherapy predict the treatment response and prognosis in stage II/III breast cancer.
Liu B; Su F; Li Y; Qi X; Liu X; Liang W; You K; Zhang Y; Zhang J
Biomed Pharmacother; 2017 Apr; 88():911-917. PubMed ID: 28178621
[TBL] [Abstract][Full Text] [Related]
19. The importance of stromal and intratumoral tumor lymphocyte infiltration for pathologic complete response in patients with locally advanced breast cancer.
Eryilmaz MK; Mutlu H; Ünal B; Salim DK; Musri FY; Coşkun HŞ
J Cancer Res Ther; 2018; 14(3):619-624. PubMed ID: 29893329
[TBL] [Abstract][Full Text] [Related]
20. Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients.
Graziano V; Grassadonia A; Iezzi L; Vici P; Pizzuti L; Barba M; Quinzii A; Camplese A; Di Marino P; Peri M; Veschi S; Alberti S; Gamucci T; Di Gioacchino M; De Tursi M; Natoli C; Tinari N
Breast; 2019 Apr; 44():33-38. PubMed ID: 30611095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
